Quality of life in head and neck cancer patients: Impact of HPV and primary treatment modality

Jessica H. Maxwell, Vikas Mehta, Hong Wang, Diana Cunningham, Umamaheswar Duvvuri, Seungwon Kim, Jonas Johnson, Robert L. Ferris

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Objectives/Hypothesis To determine posttreatment quality of life (QOL) in head and neck cancer patients, stratifying by human papillomavirus (HPV)/p16 status and primary treatment modality. Study Design Retrospective study. Methods One hundred and seventy-seven patients (N=177) with head and neck squamous cell carcinoma and known HPV/p16 status were included. All patients completed at least one baseline or posttreatment University of Washington QOL survey. QOL scores were averaged and compared across patients, stratifying by HPV/p16 status and primary treatment modality (surgical vs. nonsurgical). In the analysis, p16 was used as a surrogate marker for HPV. Results Of the 177 patients, 80 (45.2%) were p16-positive and 49.7% of subsites were oropharyngeal. Nearly 60% (105/177) of patients underwent primary surgery, 26.7% (28/105) of patients with transoral robotic or laser techniques. The remainder 40.7% of patients underwent primary radiation and/or chemotherapy. Overall, QOL scores were better for p16-positive patients compared to p16-negative patients at baseline (P=0.008), at 6 months posttreatment (P=0.034), and at greater than 1 year posttreatment (P=0.013). P16-positive patients had better QOL scores in speech (P=0.0009), chewing (P=0.0004), and swallowing (P=0.021) after 1 year posttreatment compared to p16-negative patients. Primary treatment modality did not affect overall QOL or any of the 12 QOL categories in p16-positive patients at any time point. At over 1 year posttreatment, QOL was at or above baseline in both p16-positive treatment groups. Conclusion The p16-positive patients had better baseline and posttreatment overall QOL compared to p16-negative patients. The overall and category specific QOL scores for p16-positive patients were not affected by primary treatment modality. Level of Evidence 4. Laryngoscope, 124:1592-1597, 2014

Original languageEnglish (US)
Pages (from-to)1592-1597
Number of pages6
JournalLaryngoscope
Volume124
Issue number7
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Head and Neck Neoplasms
Quality of Life
Therapeutics
Laryngoscopes
Mastication
Robotics
Deglutition

Keywords

  • head and neck squamous cell carcinoma
  • HPV
  • p16
  • Quality of life

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Maxwell, J. H., Mehta, V., Wang, H., Cunningham, D., Duvvuri, U., Kim, S., ... Ferris, R. L. (2014). Quality of life in head and neck cancer patients: Impact of HPV and primary treatment modality. Laryngoscope, 124(7), 1592-1597. https://doi.org/10.1002/lary.24508

Quality of life in head and neck cancer patients : Impact of HPV and primary treatment modality. / Maxwell, Jessica H.; Mehta, Vikas; Wang, Hong; Cunningham, Diana; Duvvuri, Umamaheswar; Kim, Seungwon; Johnson, Jonas; Ferris, Robert L.

In: Laryngoscope, Vol. 124, No. 7, 2014, p. 1592-1597.

Research output: Contribution to journalArticle

Maxwell, JH, Mehta, V, Wang, H, Cunningham, D, Duvvuri, U, Kim, S, Johnson, J & Ferris, RL 2014, 'Quality of life in head and neck cancer patients: Impact of HPV and primary treatment modality', Laryngoscope, vol. 124, no. 7, pp. 1592-1597. https://doi.org/10.1002/lary.24508
Maxwell, Jessica H. ; Mehta, Vikas ; Wang, Hong ; Cunningham, Diana ; Duvvuri, Umamaheswar ; Kim, Seungwon ; Johnson, Jonas ; Ferris, Robert L. / Quality of life in head and neck cancer patients : Impact of HPV and primary treatment modality. In: Laryngoscope. 2014 ; Vol. 124, No. 7. pp. 1592-1597.
@article{8ddb998c1d434af0b952f2b09fa232d1,
title = "Quality of life in head and neck cancer patients: Impact of HPV and primary treatment modality",
abstract = "Objectives/Hypothesis To determine posttreatment quality of life (QOL) in head and neck cancer patients, stratifying by human papillomavirus (HPV)/p16 status and primary treatment modality. Study Design Retrospective study. Methods One hundred and seventy-seven patients (N=177) with head and neck squamous cell carcinoma and known HPV/p16 status were included. All patients completed at least one baseline or posttreatment University of Washington QOL survey. QOL scores were averaged and compared across patients, stratifying by HPV/p16 status and primary treatment modality (surgical vs. nonsurgical). In the analysis, p16 was used as a surrogate marker for HPV. Results Of the 177 patients, 80 (45.2{\%}) were p16-positive and 49.7{\%} of subsites were oropharyngeal. Nearly 60{\%} (105/177) of patients underwent primary surgery, 26.7{\%} (28/105) of patients with transoral robotic or laser techniques. The remainder 40.7{\%} of patients underwent primary radiation and/or chemotherapy. Overall, QOL scores were better for p16-positive patients compared to p16-negative patients at baseline (P=0.008), at 6 months posttreatment (P=0.034), and at greater than 1 year posttreatment (P=0.013). P16-positive patients had better QOL scores in speech (P=0.0009), chewing (P=0.0004), and swallowing (P=0.021) after 1 year posttreatment compared to p16-negative patients. Primary treatment modality did not affect overall QOL or any of the 12 QOL categories in p16-positive patients at any time point. At over 1 year posttreatment, QOL was at or above baseline in both p16-positive treatment groups. Conclusion The p16-positive patients had better baseline and posttreatment overall QOL compared to p16-negative patients. The overall and category specific QOL scores for p16-positive patients were not affected by primary treatment modality. Level of Evidence 4. Laryngoscope, 124:1592-1597, 2014",
keywords = "head and neck squamous cell carcinoma, HPV, p16, Quality of life",
author = "Maxwell, {Jessica H.} and Vikas Mehta and Hong Wang and Diana Cunningham and Umamaheswar Duvvuri and Seungwon Kim and Jonas Johnson and Ferris, {Robert L.}",
year = "2014",
doi = "10.1002/lary.24508",
language = "English (US)",
volume = "124",
pages = "1592--1597",
journal = "Laryngoscope",
issn = "0023-852X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Quality of life in head and neck cancer patients

T2 - Impact of HPV and primary treatment modality

AU - Maxwell, Jessica H.

AU - Mehta, Vikas

AU - Wang, Hong

AU - Cunningham, Diana

AU - Duvvuri, Umamaheswar

AU - Kim, Seungwon

AU - Johnson, Jonas

AU - Ferris, Robert L.

PY - 2014

Y1 - 2014

N2 - Objectives/Hypothesis To determine posttreatment quality of life (QOL) in head and neck cancer patients, stratifying by human papillomavirus (HPV)/p16 status and primary treatment modality. Study Design Retrospective study. Methods One hundred and seventy-seven patients (N=177) with head and neck squamous cell carcinoma and known HPV/p16 status were included. All patients completed at least one baseline or posttreatment University of Washington QOL survey. QOL scores were averaged and compared across patients, stratifying by HPV/p16 status and primary treatment modality (surgical vs. nonsurgical). In the analysis, p16 was used as a surrogate marker for HPV. Results Of the 177 patients, 80 (45.2%) were p16-positive and 49.7% of subsites were oropharyngeal. Nearly 60% (105/177) of patients underwent primary surgery, 26.7% (28/105) of patients with transoral robotic or laser techniques. The remainder 40.7% of patients underwent primary radiation and/or chemotherapy. Overall, QOL scores were better for p16-positive patients compared to p16-negative patients at baseline (P=0.008), at 6 months posttreatment (P=0.034), and at greater than 1 year posttreatment (P=0.013). P16-positive patients had better QOL scores in speech (P=0.0009), chewing (P=0.0004), and swallowing (P=0.021) after 1 year posttreatment compared to p16-negative patients. Primary treatment modality did not affect overall QOL or any of the 12 QOL categories in p16-positive patients at any time point. At over 1 year posttreatment, QOL was at or above baseline in both p16-positive treatment groups. Conclusion The p16-positive patients had better baseline and posttreatment overall QOL compared to p16-negative patients. The overall and category specific QOL scores for p16-positive patients were not affected by primary treatment modality. Level of Evidence 4. Laryngoscope, 124:1592-1597, 2014

AB - Objectives/Hypothesis To determine posttreatment quality of life (QOL) in head and neck cancer patients, stratifying by human papillomavirus (HPV)/p16 status and primary treatment modality. Study Design Retrospective study. Methods One hundred and seventy-seven patients (N=177) with head and neck squamous cell carcinoma and known HPV/p16 status were included. All patients completed at least one baseline or posttreatment University of Washington QOL survey. QOL scores were averaged and compared across patients, stratifying by HPV/p16 status and primary treatment modality (surgical vs. nonsurgical). In the analysis, p16 was used as a surrogate marker for HPV. Results Of the 177 patients, 80 (45.2%) were p16-positive and 49.7% of subsites were oropharyngeal. Nearly 60% (105/177) of patients underwent primary surgery, 26.7% (28/105) of patients with transoral robotic or laser techniques. The remainder 40.7% of patients underwent primary radiation and/or chemotherapy. Overall, QOL scores were better for p16-positive patients compared to p16-negative patients at baseline (P=0.008), at 6 months posttreatment (P=0.034), and at greater than 1 year posttreatment (P=0.013). P16-positive patients had better QOL scores in speech (P=0.0009), chewing (P=0.0004), and swallowing (P=0.021) after 1 year posttreatment compared to p16-negative patients. Primary treatment modality did not affect overall QOL or any of the 12 QOL categories in p16-positive patients at any time point. At over 1 year posttreatment, QOL was at or above baseline in both p16-positive treatment groups. Conclusion The p16-positive patients had better baseline and posttreatment overall QOL compared to p16-negative patients. The overall and category specific QOL scores for p16-positive patients were not affected by primary treatment modality. Level of Evidence 4. Laryngoscope, 124:1592-1597, 2014

KW - head and neck squamous cell carcinoma

KW - HPV

KW - p16

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=84903143448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903143448&partnerID=8YFLogxK

U2 - 10.1002/lary.24508

DO - 10.1002/lary.24508

M3 - Article

C2 - 24353066

AN - SCOPUS:84903143448

VL - 124

SP - 1592

EP - 1597

JO - Laryngoscope

JF - Laryngoscope

SN - 0023-852X

IS - 7

ER -